Systemic Anti-Cancer Therapy Electronic Prescribing System - Market Engagement

University Hospitals Birmingham NHS Foundation Trust (the "Authority") is conducting market engagement in relation to its requirement for a Electronic Prescribing solution for System Anti-Cancer Therapy (SACT).

University Hospitals Birmingham NHS Foundation Trust ("UHB") is a large specialist teaching hospital that runs the Queen Elizabeth Hospital Birmingham (QEHB), Birmingham Chest Clinic, Heartlands Hospital (BHH), Good Hope Hospital (GHH), Solihull Hospital (SH) and various community services across the region.

The Trust is looking to source a solution which replaces the current ways of working for prescribing systemic anti-cancer therapy (SACT) for patients attending its four hospital sites. The aim is to procure a designated SACT electronic prescribing system that will provide a robust, up to date and safe prescribing platform for patients requiring SACT and in doing so reduce prescribing errors, eradicate paper prescriptions, improve operational performance, improve patient safety and outcomes, and improve ways of working for staff.

Suppliers who are able to offer solutions relevant to this requirement are invited to express an interest and respond to a market engagement questionnaire.

Suppliers wishing to participate in this market engagement exercise and express an interest in this requirement should respond to the questionnaire via the online form on the Health Family Single eCommercial System Portal (Atamis) by 13:00 on Monday 30th October 2023.

https://atamis-1928.my.salesforce-sites.com/ProSpend__CS_ContractPage?SearchType=Projects&uid=a078d000004zElaAAE&searchStr=&sortStr=Recently+Published&page=1&filters=&County=